ArticleNanomedicine : nanotechnology, biology, and medicine2015
Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Charting new frontiers in nanoparticle immunotoxicity: A perspective on current, emerging, and future approaches.Biochemical and biophysical research communications · 2025Review
- Nucleic acid nanobiosystems for cancer theranostics: an overview of emerging trends and challenges.Nanomedicine (London, England) · 2025Review
- Assessment of the gold nanoparticles biosynthesized using Casuarina equisetifolia bark extract against the ethion induced Hepato- and neurotoxicity in rats.Journal, genetic engineering & biotechnology · 2025Article
- Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.International journal of molecular sciences · 2024Article
- Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.Nature nanotechnology · 2022Review
- Chemotherapy Side-Effects: Not All DNA Damage Is Equal.Cancers · 2022Review
- The Preventive Effects of Naringin and Naringenin against Paclitaxel-Induced Nephrotoxicity and Cardiotoxicity in Male Wistar Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.Frontiers in immunology · 2022Review
- Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response.iScience · 2021Article
- Differences in Fatty Acid Oxidation betweenACS omega · 2021Article
- Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier.Molecules (Basel, Switzerland) · 2021Article
- RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition.Advanced functional materials · 2018Article
- Unintended effects of drug carriers: Big issues of small particles.Advanced drug delivery reviews · 2018Review
- Main trends of immune effects triggered by nanomedicines in preclinical studies.International journal of nanomedicine · 2018Review
- Current understanding of interactions between nanoparticles and the immune system.Toxicology and applied pharmacology · 2016Review
- Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Understanding the ability of cytotoxic oncology drugs, and their carriers and formulation excipients, to induce pro-inflammatory responses is important for establishing safe and efficacious formulations. Literature data about cytokine response induction by the traditional formulation of paclitaxel, Taxol®, are controversial, and no data are available about the pro-inflammatory profile of the nano-albumin formulation of this drug, Abraxane®. Herein, we demonstrate and explain the difference in the cytokine induction profile between Taxol® and Abraxane®, and describe a novel mechanism of cytokine induction by a nanosized excipient, Cremophor EL, which is not unique to Taxol® and is commonly used in the pharmaceutical industry for delivery of a wide variety of small molecular drugs. FROM THE CLINICAL EDITOR: Advances in nanotechnology have enabled the production of many nano-formulation drugs. The cellular response to drugs has been reported to be different between traditional and nano-formulations. In this article, the authors investigated and compared cytokine response induction profiles between Taxol® and Abraxane®. The findings here provided further understanding to create drugs with better safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.